• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi in India – Highlights from 2019

Home > News

DNDi in India – Highlights from 2019

30 Jul 2020
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

DNDi 15th Anniversary and launch of a special collection on Neglected Diseases and Innovation in South Asia with The BMJ

DNDi celebrated its 15th anniversary and organized a stakeholders meeting at India International Centre, New Delhi in collaboration with Indian Council of Medical Research (ICMR). Prof. Balram Bhargava, Secretary, Department of Health Research & Director General, ICMR, Dr Renu Swarup, Secretary, Department of Bio Technology, GoI, Dr Shekhar C Mande, Secretary, DSIR and Director General, Council of Scientific & Industrial Research, Leena Menghaney, Head, South Asia, MSF Access Campaign were among the participants, as were about 100 DNDi partners, including key policy makers, public and private sector representatives, pharmaceutical industry partners, the Bill and Melinda Gates Foundation, Tata Trust, MSF, and international NGOs. DNDi spoke about the organization’s achievements in the field of neglected diseases and discussed new opportunities for R&D and innovation for neglected patients.

On the occasion, DNDi launched a special collection of articles entitled ‘Neglected Diseases and Innovation in South Asia’ published by The BMJ (formerly The British Medical Journal). The collection brings together over 30 authors from across South Asia and the globe to identify research priorities and recommendations for action to improve the health of neglected patients in the region. The collection maps progress in the control or elimination of neglected diseases such as lymphatic filariasis and kala-azar, examines disease burden and gaps in access to treatment for snakebite envenoming in the region, and highlights the growing challenge of antimicrobial resistance.

Dr Suman Rijal, Director, DNDi in India; Dr Renu Swarup, Secretary, DBT; Prof. Balram Bhargava, Secretary, DHR and DG, ICMR; Dr Bernard Pécoul, Executive Director, DNDi; and Leena Menghaney, Head, South Asia, MSF Access
(Left to right) Dr Suman Rijal, Director, DNDi in India; Dr Renu Swarup, Secretary, DBT; Prof. Balram Bhargava, Secretary, DHR and DG, ICMR; Dr Bernard Pécoul, Executive Director, DNDi; and Leena Menghaney, Head, South Asia, MSF Access Campaign launching a special collection of articles entitled ‘Neglected Diseases and Innovation in South Asia’ published by The BMJ.

The unifying theme of the collection is innovation in diagnostics and treatment, and the need to create solutions for neglected patients that are effective, relevant, locally feasible, and sustainable. India has a unique role to play given its high disease burden and expertise in end-to-end solutions, from drug discovery and clinical studies, through to regulation, manufacture, and distribution. The articles highlight the notable successes of public health programmes in neglected diseases in South Asia and identify areas where research and supportive policy are needed to sustain plans for control or elimination. Authors also called for a comprehensive policy for neglected diseases research in India to foster innovation in drugs, diagnostics, and vaccines, critical to addressing the evolving needs of elimination programmes.

Elimination of vector-borne diseases: current gaps and the need for new tools

DNDi and ICMR-National Institute of Malaria Research, New Delhi, organized a day-long symposium to address different aspects of neglected tropical diseases that have been targeted for elimination – namely lymphatic filariasis, visceral leishmaniasis (VL), and malaria. Experts discussed the gaps in the elimination programme and research for new tools, and identified opportunities to overcome them.   

Though visceral leishmaniasis cases in India have decreased, there is still a need for better tools – e.g., better diagnostics for visceral leishmaniasis relapse and post-kala-azar dermal leishmaniasis (PKDL), and better treatments, including for PKDL and HIV-VL coinfection. Experts recommended the development of algorithms for cost-effective management of febrile illness in endemic regions. It was felt that the definition of death due to visceral leishmaniasis needs to be clearly defined so it can be accurately captured in outcome assessments. There was also agreement on the need to focus on the role of asymptomatic leishmania infection in transmission.

Challenges to lymphatic filariasis elimination include failure of drug dosage and lack of drug monitoring and management of hotspots. A promising new combination therapy for lymphatic filariasis known as IDA that combines a single dose of ivermectin (IVM), diethylcarbamazine (DEC), and albendazole (ALB) appears to be highly effective, and its safety has been evaluated in large community-based studies in several locations. Morbidity management and disability prevention (MMDP) coverage for lymphatic filariasis needs to reach to 100% of people living in at-risk areas.

In the field of malaria, experts focused on unmet medical needs related to resistance, prevention of relapse, transmission blocking, severe malaria, single-dose cures, and chemoprevention. New treatments to prevent relapse of P. vivax malaria are in development. Discussions were held on the challenges of effective vector control and many novel interventions. A panel discussion on improving surveillance for malaria elimination considered strategies including public-private partnership models.

Hope for new treatment regimen for neglected patients with HIV-VL co-infection in India   

DNDi was a technical partner in an MSF-sponsored study in Bihar state to evaluate treatments with liposomal amphotericin B (LAmB) monotherapy and a combination of LAmB and miltefosine that will provide key evidence to national and regional decision-makers on the best treatment for patients with HIV-VL coinfection. Findings from the study will also inform the national road map for visceral leishmaniasis elimination in India.

Existing treatments for visceral leishmaniasis in HIV co-infected patients are not based on evidence from the region, and more effective treatment regimens are needed. The diagnosis of visceral leishmaniasis is also a challenge in low-income settings where there is a lack of awareness about the disease, poor access to early diagnosis and referral for appropriate treatment and stigma around HIV.

Previous Indian treatment guidelines for visceral leishmaniasis did not differentiate treatment of HIV-VL co-infected patients from that of other patients presenting with visceral leishmaniasis. A total of 150 patients have been enrolled in the study, and the results will be published and presented to the World Health Organization and the Indian government to inform potential policy change.

Boy sitting on a hospital bed

Clinical trial for PKDL patients in South Asia

A Phase II study of LAmB monotherapy and a combination of LAmB and miltefosine is ongoing in India and Bangladesh to assess safety and efficacy for treating PKDL. This study primarily aims to improve current treatment options for PKDL patients in South Asia.

A total of 126 patients were recruited in the study in India and Bangladesh by the end of 2019. If the proposed regimen proves to be safe and efficacious, it may be possible to provide PKDL patients with shorter-duration treatments, which in turn may increase adherence to treatment.

The results of this trial will be presented to the Kala-azar National Control Programme of the Indian Ministry of Health and could lead to national policy change for PKDL treatment, if supported by the evidence.

The partners in this project in India are Kala Azar Medical Research Centre, Institute of Medical Sciences, Banaras Hindu University, and Rajendra Memorial Research Institute of Medical Sciences, and in Bangladesh, International Centre for Diarrhoeal Disease Research, Dhaka and SK Hospital, Mymensingh.

The Lead Optimisation Consortium in India (LOCI)

With many world-class research institutions and global pharmaceutical organizations, India is rich in both scientific expertise and drug discovery capabilities. To engage with this ecosystem further and to uncover new potential treatments for diseases of significant relevance to India, DNDi has initiated the Lead Optimisation Consortium in India (LOCI) with relevant stakeholders in the country. Initially, partners will work together to discover and optimize new pre-clinical drug candidates for leishmaniasis. With this initiative, we also hope to foster cross-regional and cross-institutional collaboration across the Indian drug discovery ecosystem and deepen our engagement within the country.

LOCI brings together DNDi, IIT Gandhinagar, and the Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management at Narsee Monjee Institute of Management Studies (NMIMS). The collaboration plans to expand to other institutes in India with the purpose of engaging students and young researchers to apply their talents to discovering molecules for potential new treatments for neglected tropical diseases.

Refresher training on revised clinical trial rules in India 

India’s New Drug and Clinical Trials Rules were revised in March 2019. DNDi organized a training for its clinical staff, including Ethics Committee members at the sites where DNDi conducts clinical trials, to apprise them of all the changes. Since its inception in 2003, DNDi has integrated capacity strengthening in all its projects.

People attending a training
Refresher training on revised clinical trial rules in India with partners

The two-day training was organized at Rajendra Prasad Medical Research Institute (RMRI), Patna in September. Around 60 participants from RMRI, Kala Azar Medical Research Centre in Muzaffarpur, MSF, and DNDi attended this training, which was well received. Participants were trained on the revised regulatory framework and requirements for clinical trials in India as per International Conference on Harmonisation Good Clinical Practice (ICH-GCP) and Indian regulations. The new changes bring better clarity, define responsibilities, stress accountability, and harmonize requirements for imports and clinical trials.

Photo credits: Kishore Pandit-DNDi, DNDi, Maneesh Agnihotri-DNDi, Ranjan Rahi

Clinical trials Drug discovery Partnership Strengthening Capacities Malaria Visceral leishmaniasis India

Read, watch, share

Loading...
Doctor with patient
News
5 Jun 2023

Marking DNDi’s 20th year of driving medical innovation for the most neglected

Mother and child smiling
News
1 Jun 2023

Statement from Dr Luis Pizarro, Executive Director of DNDi, about the Princess of Asturias Award for International Cooperation

Statements
24 May 2023

DNDi interventions at the 76th World Health Assembly

Statements
19 May 2023

DNDi’s briefing note for 76th World Health Assembly

Viewpoints
14 Apr 2023

Bringing Chagas disease care closer to people who need it

Mother standing in front of her adolescent son
Stories
13 Apr 2023

Diagnosis & treatment closer to patients

Woman holding pills in her hand
Press releases
12 Apr 2023

Publication demonstrates how equitable deals for access to medicines can be signed with pharmaceutical industry

Researchers in lab environment
Press releases
7 Apr 2023

eWHORM project launched to eliminate worm infections in Sub Saharan Africa

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
This website uses necessary cookies to function. If you give your consent, we will also use statistical, functional, and marketing cookies. See Cookie Policy.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo